Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (September 2013)
19 slides from Coloplast A/s Class B's roadshow presentation, Sep 9, 2013
Slide 1: Coloplast in China
Coloplast in China Presentation to Nordea Markets 9 September 2013
Slide 2: Who are we?
Who are we? Vagn Heiberg SVP Region China Mikkel Dalgaard Heuer Director, Wound Care, Region China Michael Juhl Petersen Holtze Director, Business Support, Region China Hu Zhan Head of Public and Regulatory Affairs, Region China
Slide 3: China is the fastest growing region for Coloplast
China represents the fastest growing region for Coloplast, and today more than 500 people are employed in our commercial activities in China >500
Slide 4: Main business drivers are Ostomy Care and Wound Care
Our main business drivers in the region are Ostomy Care and Wound Care, which account for ~90% of our total revenue. Within both of these business areas we have achieved market leadership in China Ostomy Care Wound Care Continence Care Ostomy products include ostomy Wound care products include Conti
Slide 5: The Ambition Plan evolves around 5 main strategic themes
The Ambition Plan evolves around 5 main strategic themes and a number of commercial priorities to support them 1 Raise productivity 2 Increase coverage 3 Grow the market 4 Pursue new opportunities 5 Train and retain
Slide 6: A robust organizational structure to execute
And we have built a robust organizational structure to execute on both our short term tactical objectives and our long term strategic ambitions Vagn Heiberg SVP Region China Jesper L. Thomsen Mikkel D. Heuer Michael J. P. Holtze AP von Scholten Illum Hu Zhan Director Director Director Director Head
Slide 7: Current reimbursement status: wide coverage, low benefit level
The current reimbursement status is “wide coverage, low benefit level” with a future trend of getting more funding from both central and provincial governments Different reimbursement OOP as % in total health expenditure schemes in China 70% 60% 8% 60% 14% 50% 40% 38% 17% 40% 61% 30% 20% 13% 10% 10%
Slide 8: OC enjoys better reimbursement status than WSC
OC enjoy a better reimbursement status than WSC, as it is recognized to be “must have” for a fixed number of patients Current CP product reimbursement status in China OC products WSC products 50% 50% 42% 34% 15% (National Average) 12% 9% 6% (National Average) 1% 0% 1% Provinces 0% Provinces Jiangsu
Slide 9: Business Support China
Business Support China Business Support Director Compliance Manager Finance & Distribution/ Commercial IT Training HR Admin Warehousing Department Department Department Department Department Accounts R Pick, Pack and Distributor Support Training Recruiting Accounts P ship goods Management Infrastruc
Slide 10: Reducing employee turnover as a key strategic theme
One of our key strategic themes is to reduce employee turnover, and in the past years we have been able to reduce the turnover rate dramatically by improving leadership skills and by optimizing the compensation and benefits packages 35.0% Drivers for reduction in turnover 30.0% 25.0% • Leading to Wi
Slide 11: OC market growth driven by improving healthcare system
OC market growth is mainly driven by an improving healthcare system and changes in population Market size and growth Market dynamics Market value growth drivers • Aging of population Low cost OC bags • Number of surgeries increasing 0-5% Mid/high priced OC bags • Product upgrading in hospitals • Imp
Slide 12: Expanding Direct to Consumer 24/7 business
By expanding our Direct to Consumer 24/7 business we will gain a stronger position in the growing community market ▪ Coloplast China already has a well- developed Direct to Consumer (DtC24/7) sales platform. ▪ CARE has been launched Mail Order Online service sales Direct to ▪ Increase the number of
Slide 13: Continence Care focus on key Rehabilitation Centers
In Continence Care we will focus on the most important Rehabilitation Centers and Departments in China to increase the use of intermittent catheters in China Rehab. Status • Top 20 Rehab hospitals/ Departments • Approx. 2,200 beds • 60 % of patients are SCI patients
Slide 14: China wound care market development trends
In Wound Care the overall development trends in China are still expected to be favorable to Coloplast in the years ahead Total China wound care market – traditional and advanced - mDKK 8000 Changing lifestyle 7000 Aging 6000 society 5000 Healthcare 4000 reforms 3000 Private Insurance 2000 Increasing
Slide 15: Wound Care team faces toughest competition ever
While our WC team is stronger than ever it is also facing the toughest competition ever – mainly from international players Player rank estimate* H1 FY12/13 Comments 1 No strong local 2 competitors on the short term (1-2 years) 3 on the medium term (3-5 4 years) strong domestic 5 competitors is ex
Slide 16: FY 12/13 ambition to retain leading position in wound healing
In FY 12/13 we set out with the ambition to retain our leading position in moist wound healing for chronic wounds 1 • Realizing the potential in our stronghold indications Build Biatain Grow Comfeel 2 • Developing new business areas Build business with doctors Execute AtH community project 3
Slide 17: China's Ambition Plan: becoming a top 5 market
We expect the growth journey to continue, and Region China’s Ambition Plan lays out the strategic direction for developing China into becoming one of the top 5 markets for Coloplast China growth ambition Top Coloplast Markets (est.) 1 USA 15 2 UK CAGR 3 France >XX% 4 China WSC 5 Germany CC OC 10/11
Slide 18: Questions
Questions Ostomy Care Urology & Continence Care = Coloplast Wound & Skin Care
Slide 19: Our mission, values and vision
Our mission Making life easier for people with intimate healthcare needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding Coloplast